
Image Credit: Man & Science
Man & Science reports that all ten participants in its ONFIELD first-in-human pilot study have received and activated its investigational occipital nerve stimulation system for refractory chronic cluster headache. The device combines its receiver and stimulation lead in one subcutaneous implant at the back of the head. It has no implanted battery and receives power from a unit worn behind the ear.
The company reports reduced attack frequency in participants assessed so far and no serious adverse events related to implantation or the device. It has not published numerical response data in this announcement. Follow-up continues, with a pivotal study planned subject to the pilot findings and regulatory requirements.
